Second cancers after treatment for Hodgkin's disease.
| Group/Reference . | Patients/Treatment . | N . | MDS/Leukemia . | Solid Tumors . | Time (Yr) . |
|---|---|---|---|---|---|
| * Figures indicate non-Hodgkin's lymphoma only | |||||
| Abbreviations: see Table 3; MDS, myelodysplastic syndrome | |||||
| Chemotherapy Only | |||||
| ECOG | IIIA2,IIIB, IV, after RT | 691 | 8 | ||
| MOPP → ABVD | 9 | N/A | |||
| MOPP/ABV | 1 | N/A | |||
| CALGB | III, IV, after RT | 856 | 3 | ||
| ABVD | 0 | 2 | |||
| MOPP/ABV | 6 | 6 | |||
| Chemotherapy + Radiotherapy | |||||
| Milan | IB, IIAbulky,IIB, III, IV | 427 | 11 | 12 | 10 |
| MOPP/ABVD + RT | |||||
| Hybrid + RT | |||||
| GHSG | IIB-IIIArisk, IIIB, IV | 1180 | 3 | ||
| COPP/ABVD | 233 | 0 | 6* | ||
| BEACOPP | 457 | 2 | 4* | ||
| EscBEACOPP | 460 | 8 | 4* | ||
| Group/Reference . | Patients/Treatment . | N . | MDS/Leukemia . | Solid Tumors . | Time (Yr) . |
|---|---|---|---|---|---|
| * Figures indicate non-Hodgkin's lymphoma only | |||||
| Abbreviations: see Table 3; MDS, myelodysplastic syndrome | |||||
| Chemotherapy Only | |||||
| ECOG | IIIA2,IIIB, IV, after RT | 691 | 8 | ||
| MOPP → ABVD | 9 | N/A | |||
| MOPP/ABV | 1 | N/A | |||
| CALGB | III, IV, after RT | 856 | 3 | ||
| ABVD | 0 | 2 | |||
| MOPP/ABV | 6 | 6 | |||
| Chemotherapy + Radiotherapy | |||||
| Milan | IB, IIAbulky,IIB, III, IV | 427 | 11 | 12 | 10 |
| MOPP/ABVD + RT | |||||
| Hybrid + RT | |||||
| GHSG | IIB-IIIArisk, IIIB, IV | 1180 | 3 | ||
| COPP/ABVD | 233 | 0 | 6* | ||
| BEACOPP | 457 | 2 | 4* | ||
| EscBEACOPP | 460 | 8 | 4* | ||